Europe Articaine Hydrochloride Market

Europe Articaine Hydrochloride Market Size & Growth (2023 to 2028):

As per the research report, the size of the European Articaine Hydrochloride market was valued at USD 0.48 billion in 2023 and is expected to reach USD 0.67 billion by 2028 to grow at 7.12% CAGR during the forecast period 2023 to 2028.

The European articaine hydrochloride market is predicted to grow due to the increasing focus on oro-facial treatments. Rising awareness of aesthetics, preventive and corrective treatments in European countries is also one of the growth factors of this market. Many dental specialists are exploring the benefits of articaine hydrochloride as a local anesthetic as a replacement for lidocaine hydrochloride, the first preferred choice for an anesthetic agent. Articaine hydrochloride works as a better alternative in performing more efficient procedures and allows better clinical care.

Articaine hydrochloride is Germany's most popular anesthetic choice, where about 97.5% of dentists use it. Increased incidence of dental caries and other dental diseases, successful research and development supported with clinical trials, and advancements in dental anesthesia system devices are anticipated to drive the market's growth. Periodontal disease is a significant dental disease affecting human populations worldwide with high prevalence rates. In Italy, the prevalence of periodontal diseases will grow over time. In 2019, approximately 15.88 thousand Italians out of 100,000. According to the CDC, most periodontitis was 70.98% to 87.42% in the German population, with prevalence significantly higher in males.

Lack of primary oral health education and limited availability of simple interventions such as pain relief and emergency care for acute infections and injuries for the vast majority of the population are the main reasons for the region's higher incidence of dental diseases. The prevalence of the periodontal disease has been reported to be 20-50% worldwide. In 2010, the global productivity loss due to severe periodontitis was estimated at the US $ 54 billion per year. The prevalence of periodontal disease will increase in the coming years due to increased retention of natural teeth due to a massive reduction in tooth loss in the older population.

On the other hand, the high costs of dental procedures and unfavorable reimbursement policies will hamper the market's growth. Additionally, side effects and insufficient drug knowledge about articaine hydrochloride use will challenge the European articaine hydrochloride market.

This research report on the Europe Articaine Hydrochloride Market has been segmented and sub-segmented into the following categories:

By Application:

• Infiltration
• Nerve Block
• Others

By End User:

• Dental Clinics
• Hospitals
• Academic
• Research Institutes

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Germany articaine hydrochloride market holds the largest market share and will dominate the global market during the forecast period due to the increasing demand and focus on dental treatment, well-developed healthcare facilities, supportive government initiatives to increase oral care awareness, high disposable income, and a growing senior population prone to periodontitis and dental caries. As a result, Germany is the largest buyer of articaine hydrochloride.

Other European regions represent a significant market share due to the increased use of articaine hydrochloride by dentists in Italy and France. As per the International Classification of Periodontal Diseases, approximately 52% of adults in France suffer from the periodontal problem. Dental professionals' growing acceptance of articaine hydrochloride will drive the market's growth in these regions. In some European countries, articaine hydrochloride is the most commonly used local anesthetic in dentistry.

KEY MARKET PLAYERS:

Key players operating in the European Articaine Hydrochloride Market profiled in this report are 3M, Anhui BBCA Pharmaceutical Co., Ltd., Dentsply Sirona, Inibsa Dental S.L.U, Jinan Chenghui Shuangda Chemical Co., Ltd, Jinan Ruixing Pharmaceutical Technology Co., Ltd, Manus Aktteva Biopharma LLP, Pfizer Inc, Pierrel S.p.A, Sanofi, Septodont, Siegfried AG, and Sigma Aldrich.